5:17 PM
 | 
Jan 17, 2013
 |  BC Extra  |  Company News

FDA approves NuPathe's Zecuity for migraines

NuPathe Inc. (NASDAQ:PATH) said FDA approved an NDA for Zecuity for the acute treatment of migraine with or without aura...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >